Acer Therapeutics Inc
Change company Symbol lookup
Select an option...
ACER Acer Therapeutics Inc
CEMI Chembio Diagnostics Inc
MOJO MOJO Organics Inc
JSDA Jones Soda Co
NOBL ProShares S&P 500 Dividend Aristocrats ETF
NLY Annaly Capital Management Inc
NGG National Grid PLC
NEM Newmont Corporation
NDP Tortoise Energy Independence Fund, Inc
NCV AllianzGI Convertible & Income Fund
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Closing Price
$1.74
Day's Change
-0.255 (-12.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.89
Day's Low
1.71
Volume
(Light)
Volume:
42,307

10-day average volume:
135,398
42,307

Display:

Providers:

UpdateCancel
7 providers

No news found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.